Inovio Pharmaceu (INO) Stock News

INOVIO (NASDAQ: INO) announced that an abstract for INO-3107, targeting Recurrent Respiratory Papillomatosis (RRP), has been accepted for oral presentation at the ABEA program during the COSM 2023 in Boston, scheduled for May 5, 2023. The presentation will showcase safety and immunogenicity data from both cohorts of a recently completed Phase 1/2 trial involving 32 RRP patients. RRP, primarily caused by HPV-6 and HPV-11, leads to the growth of benign warts in the respiratory tract but can cause serious complications. INO-3107 is a clinical-stage DNA medicine aimed at inducing T cell responses against these HPV types, potentially curbing papilloma growth. In July 2020, INO-3107 received Orphan Drug Designation from the FDA.

INOVIO (NASDAQ: INO) announced a positive opinion from the European Committee for Orphan Medicinal Products (COMP) regarding its application for orphan drug designation for INO-3107, intended for treating Recurrent Respiratory Papillomatosis (RRP). This rare disease, often caused by HPV types 6 and 11, leads to small growths in the respiratory tract, posing severe risks like airway obstruction. The European Commission is expected to make a final decision by late May 2023. Orphan designation is crucial for medicines targeting rare, life-threatening diseases affecting fewer than 5 in 10,000 individuals in the EU.

INOVIO (NASDAQ: INO) announced promising results from a Phase 1b trial evaluating INO-4201 as a booster for the rVSV-ZEBOV vaccine presented at the 33rd ECCMID. Conducted by Geneva University Hospitals, the trial demonstrated that INO-4201 was well tolerated and generated a robust immune response. Preliminary data indicated that 100% of participants exhibited increased humoral responses, with significant antibody titer boosts observed after vaccination. Geometric mean titers rose markedly after booster administration, indicating potential effectiveness against Zaire ebolavirus. These developments position INO-4201 as a crucial addition to strategies against Ebola Virus Disease, highlighting its significance in public health initiatives against infectious diseases.

INOVIO (NASDAQ: INO) announced that an abstract for its DNA vaccine candidate INO-4201 has been accepted for presentation at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on April 16, 2023. This Phase 1b trial focuses on the vaccine as a booster for the rVSV-ZEBOV (Ervebo) Ebola vaccine. Lead investigator Dr. Angela Huttner will present new humoral and cellular response data during a late-breaking trial session. The trial, involving 46 participants, evaluated the safety, tolerability, and immunogenicity of INO-4201, which targets the Zaire Ebola virus and aims to enhance immune response against various ZEBOV strains. This research is significant as Ebola remains a critical health threat with ongoing outbreaks.

INOVIO (NASDAQ: INO) announced on April 3, 2023, an equity grant to its new Senior Vice President of Regulatory Affairs under the 2022 Inducement Plan. The Compensation Committee approved the award of 45,000 restricted stock units (RSUs) and options for 70,000 shares with a grant date of March 31, 2023. RSUs will vest over three years, while stock options have an exercise price of $0.82, matching the closing stock price on the grant date. The options will vest in phases, contingent on the employee's continued employment. This initiative aligns with INOVIO’s focus on developing DNA medicines against HPV-associated diseases and cancer.

INOVIO (NASDAQ: INO), a biotechnology firm focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases, announced that Jacqueline Shea, Ph.D., CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 10:40 AM ET.

Dr. Shea and the management team will engage in one-on-one meetings with investors. A webcast of the presentation will be available on the INOVIO Investor Relations Events page, with a replay accessible for 90 days post-event. INOVIO's innovative approach includes using the CELLECTRA® device to generate immune responses against targeted health threats.

INOVIO (NASDAQ: INO) announced topline results from the Phase 3 REVEAL2 trial of VGX-3100 for cervical HSIL, where it did not meet the primary endpoint in a biomarker-selected group but showed statistical significance in the all-participants population. The company reported a fourth-quarter 2022 revenue of $125,000 against total operating expenses of $56.1 million, leading to a net loss of $54.5 million. Despite challenges, INOVIO ended 2022 with $253 million in cash, sufficient to fund operations into Q1 2025. Positive preliminary data were also presented for INO-3107 and INO-4201, suggesting potential in HPV and Ebola treatment domains.

INOVIO (NASDAQ: INO) announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial for INO-3107, aimed at treating HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP). Of 11 patients, 10 (91%) experienced a reduction in surgical interventions, with a statistically significant median decrease of three surgeries compared to the previous year. The treatment was well-tolerated, and results aligned with the first cohort. The trial's successful outcomes may pave the way for further regulatory engagement and potential advancements in DNA medicine therapies.

INOVIO (NASDAQ: INO) announced that it will release its fourth quarter and year-end 2022 financial results on March 1, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. The company is focused on developing DNA medicines for HPV-associated diseases and cancer, utilizing its proprietary CELLECTRA® device. Details for accessing the live event and archived presentation are available on their investor relations website.